Skip to content

Clinical trials

Phase 2 Multiple Sclerosis, Relapsing-Remitting trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Phase: Phase 2 Clear all

98 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20024
20036
20044
20052
20064
20074
20082
20097
20108
20117
20138
20143
20155
20162
20173
20183
20194
20201
20215
20223
20232
20242
20251
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed58
Terminated19
Unknown status5
Not yet recruiting4
Recruiting4
Withdrawn3
Active, not recruiting3
Enrolling by invitation1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Biogen9
Novartis Pharmaceuticals6
Merck KGaA, Darmstadt, Germany4
Genzyme, a Sanofi Company3
GlaxoSmithKline3
Assistance Publique - Hôpitaux de Paris2
Charite University, Berlin, Germany2
Eli Lilly and Company2
GeNeuro SA2
Genentech, Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis, Relapsing-Remitting98
Multiple Sclerosis49
Demyelinating Diseases6
Multiple Sclerosis, Chronic Progressive5
Recurrence4
Autoimmune Diseases2
Nervous System Diseases2
Autoimmune Diseases of the Nervous System1
Camurati-Engelmann Syndrome1
Diffuse Cerebral Sclerosis of Schilder1

Trials

Showing 76 to 98 of 98. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.